Breakthrough in mRNA Manufacturing Platforms: Can Pfizer’s USTAT Replace Plasmid DNA?

Executive Summary

• Pfizer has introduced a new platform called USTAT (Unified Sequential Template Amplification and Transcription).

• The platform uses Rolling Circle Amplification (RCA) to establish an mRNA manufacturing process that does not rely on traditional plasmid DNA.

• The time from DNA template generation to mRNA production can potentially be reduced to approximately two days.

• RNA quality approaches that of conventional plasmid DNA-based manufacturing, although challenges such as dsRNA formation remain.

• The technology could have future implications for personalized cancer vaccines, rare disease therapeutics, and next-generation RNA therapeutics manufacturing.

Introduction: Will Future mRNA Medicines Still Need Bacteria?

Since the successful launch of COVID-19 vaccines, mRNA technology has rapidly expanded beyond infectious diseases into cancer immunotherapy, protein replacement therapies, gene editing, and regenerative medicine.

Over the past few years, most discussions have focused on:

• Better mRNA design

• Improved Lipid Nanoparticles (LNPs)

• Circular RNA

• Self-amplifying RNA

• Tissue-specific delivery technologies

However, if you have worked in mRNA drug development, you quickly realize something else:

Many times, the real bottleneck is not the RNA itself.

It is the DNA template upstream of RNA production.

Today, the vast majority of mRNA manufacturing processes rely on plasmid DNA (pDNA).

In other words, before manufacturing mRNA, we first need to manufacture DNA.

The process typically looks like this:

DNA Design

↓

Plasmid Construction

↓

Bacterial Fermentation

↓

Plasmid Purification

↓

Linearization

↓

In Vitro Transcription (IVT)

↓

mRNA

This workflow has become highly standardized.

During the COVID-19 vaccine era, companies such as Moderna and Pfizer/BioNTech relied on similar manufacturing architectures.

But this raises an interesting question:

When developing a new mRNA product, the step that often takes the most time is not the RNA itself—it is the DNA template.

As the industry moves toward:

• Personalized Cancer Vaccines

• Rare Disease Therapeutics

• On-Demand Manufacturing

DNA template production speed could become the next major bottleneck.

That is why a recent Pfizer publication caught my attention.

The authors were not developing a new RNA sequence.

They were not developing a new LNP.

Instead, they asked a more fundamental question:

Do we still need plasmid DNA?

Pfizer Is Not Reinventing RNA—They’re Reinventing How RNA Is Made

In 2026, Pfizer’s Bioprocess R&D team published an intriguing study in npj Vaccines:

USTAT: Unified Sequential Template Amplification and Transcription—a Fully Synthetic mRNA Manufacturing Platform

Unlike many RNA therapeutics papers, this study does not focus on a novel RNA sequence.

Nor does it focus on a new delivery technology.

Instead, it focuses on a fundamental question:

How should mRNA be manufactured?

The authors proposed a bold idea:

What if we could completely bypass bacterial fermentation and generate RNA directly from synthetic DNA?

Could manufacturing become:

• Faster?

• Simpler?

• More suitable for personalized medicine?

This question led to the development of USTAT.

What Exactly Is USTAT?

In simple terms, USTAT is a system that uses Rolling Circle Amplification (RCA) to generate DNA templates and then directly transcribes them into RNA.

The workflow is:

Synthetic DNA

↓

Circular DNA

↓

Rolling Circle Amplification (RCA)

↓

Linearization

↓

In Vitro Transcription (IVT)

↓

mRNA

The key difference is that USTAT eliminates the need for traditional plasmid fermentation.

There is no requirement for a bacterial production system.

Instead, DNA amplification, linearization, and RNA transcription are integrated into a continuous workflow.

If successful, the time from DNA design to mRNA production could potentially be reduced to just a few days.

Figure 1. USTAT workflow compared with traditional plasmid DNA manufacturing process. Source: LuTra Studio

The First Innovation: Keeping Only the DNA That Matters

Traditional plasmid DNA contains much more than the target gene.

Typical plasmids include:

• Antibiotic resistance genes

• Origins of replication

• Bacterial backbone sequences

These components are essential for bacterial propagation but contribute nothing to the final mRNA product.

USTAT takes a very different approach.

The DNA template contains only:

• T7 promoter

• 5′ UTR

• Coding sequence

• 3′ UTR

• Poly(A) tail

In other words, every DNA element directly contributes to RNA production.

At first glance, this may seem like a simple reduction in template size.

In reality, it represents a significant shift in thinking:

Future DNA templates may not need to come from bacteria at all.

Which Result Surprised Me the Most?

If I had to choose the most interesting finding in the paper, it would be this:

Purification actually made RNA quality worse.

The original workflow included:

RCA

↓

Purification

↓

Linearization

↓

Purification

↓

IVT

The resulting RNA quality was disappointing.

RNA integrity was only around 60%.

The researchers then performed a surprisingly simple experiment:

They removed the intermediate purification steps.

The result?

RNA integrity jumped to nearly 86%.

This finding challenges a common assumption:

More purification does not always mean better quality.

RCA generates highly branched DNA structures.

The authors hypothesized that purification may have damaged these structures, reducing their effectiveness as IVT templates.

From a process development perspective, this is a fascinating lesson.

Sometimes the biggest improvement comes not from adding steps, but from removing unnecessary ones.

Figure 2. RCA DNA hyperbranched structure and the potential impact of purification steps. Source: LuTra Studio

How Was USTAT Optimized?

The researchers then moved into classic process development mode.

They systematically evaluated:

• RCA reaction time

• Random hexamer concentration

• Buffer composition

• Salt concentration

• Additives

One particularly interesting observation involved the linearization step.

When the temperature was increased from 37°C to 50°C, RNA integrity improved further.

The likely explanation is that higher temperatures partially relax the complex RCA DNA structure, making restriction enzyme digestion more efficient.

This type of result is common in process development:

Major improvements often come not from breakthrough technologies, but from a deeper understanding of the system.

USTAT’s Final Report Card

After extensive optimization, USTAT performed remarkably well.

RNA Integrity

USTAT: ~86%

Plasmid DNA: ~91%

The gap is surprisingly small.

RNA Fidelity

RNA sequencing revealed:

• No significant mutations

• No meaningful insertions or deletions

This indicates that RCA does not compromise sequence accuracy.

5′ Capping Efficiency

Slightly lower than plasmid-derived RNA.

However, the difference was relatively modest.

dsRNA Content

This remains the largest challenge.

USTAT generated higher levels of dsRNA than conventional plasmid DNA workflows.

For RNA therapeutics, dsRNA can activate innate immune responses and reduce translation efficiency.

Additional optimization will likely be required before large-scale implementation.

Figure 3. Comparison of RNA quality metrics between USTAT and traditional plasmid DNA workflows. Source: LuTra Studio

The Most Unexpected Result: Longer Expression Duration

The authors evaluated luciferase expression in HEK293T cells.

The results were surprising.

USTAT-derived RNA showed lower expression at early time points.

However, by 48 hours, expression levels exceeded those of the plasmid-derived control.

Interestingly, the authors could not fully explain this phenomenon.

Possible explanations include:

• Differences in RNA folding

• Differences in RNA stability

• Altered translation kinetics

• Variations in dsRNA distribution

This observation deserves further investigation.

If validated, it could affect not only manufacturing strategies but potentially therapeutic performance as well.

The Real Significance of This Paper Is Not RCA

Many readers will focus on RCA.

I think that misses the bigger picture.

The most important aspect of this study is that Pfizer is challenging an assumption that has largely gone unquestioned for more than a decade:

Does mRNA really require plasmid DNA?

That is the truly disruptive idea.

If DNA templates no longer require fermentation, we could fundamentally rethink:

• Manufacturing costs

• Production speed

• Customization capabilities

• Supply chain flexibility

The mRNA Manufacturing Platform Industry Is Already Looking Beyond Plasmid DNA

Pfizer is not alone in exploring alternatives.

Several companies are already pursuing different strategies.

Touchlight

Touchlight’s Doggybone DNA (dbDNA) platform generates DNA templates using a completely cell-free process.

The technology has already entered GMP manufacturing and clinical applications.

Aldevron

In addition to traditional plasmid DNA manufacturing, Aldevron offers:

• Linear DNA

• Nucleic acid raw materials

• Support for RNA therapeutics and gene editing programs

PlasmidFactory

PlasmidFactory specializes in minicircle DNA technology.

By removing most bacterial backbone sequences, minicircle DNA reduces unnecessary genetic material.

Pfizer USTAT

Pfizer’s approach relies on RCA-based DNA amplification.

Although still in the research stage, it offers a compelling alternative pathway.

Why Could Personalized Medicine Benefit?

If every patient eventually requires a unique RNA sequence, the bottleneck may no longer be RNA design.

The bottleneck may become:

How quickly can we generate the DNA template?

Examples include:

Personalized Cancer Vaccines

Every patient’s neoantigens are different.

Rare Disease Therapies

Small patient populations require flexible manufacturing strategies.

On-Demand Manufacturing

Future applications could include:

• Pandemic response

• Military medicine

• Remote healthcare settings

USTAT may or may not ultimately serve these applications.

But it highlights an important direction for the field.

LuTra Studio Observation

Viewed within a broader industry context, this paper suggests that future competition in mRNA therapeutics may not simply be about designing better RNA.

It may increasingly be about manufacturing.

COVID-19 demonstrated the power of RNA.

The era of personalized medicine may force the industry to rethink the value of DNA templates.

The next competitive advantage may come not from better RNA design, but from faster and more flexible RNA manufacturing.

LuTra Studio Technical & CMC Strategy Consulting

LuTra Studio provides technical and strategic consulting services for biotechnology and life science organizations, including:

• mRNA Platform Development

• DNA Template Strategy Assessment

• LNP Delivery Technologies

• Process Development & Scale-Up

• CMC Strategy Planning

• CDMO Selection & Technical Due Diligence

• Emerging RNA Manufacturing Technologies

From scientific innovation to commercialization, the challenge is often not generating the first promising result.

The real challenge is transforming a technology into a scalable, manufacturable, regulatory-ready platform.

References

Ghosh S, Simms CL, Rohrer SD, Castaneda CH, Saelens JW, Niehaus K, Swyers MJ, Russo J., USTAT: Unified Sequential Template Amplification and Transcription—a fully synthetic mRNA manufacturing platform. Npj Vaccines. 2026;11:112. DOI: https://doi.org/10.1038/s41541-026-01434-8

LuTra Studio Note

This article is primarily based on Pfizer’s USTAT study published in npj Vaccines and publicly available industry information. Discussions regarding DNA template platforms, personalized medicine, and future RNA manufacturing trends reflect the author’s personal observations and analysis and do not represent the official positions of the companies mentioned or predict future commercialization outcomes.